readthroughSign in
Nov 10, 2026Financing

Eupraxia sets up at-the-market equity program worth up to $125 million

The clinical-stage biotech established an ATM facility with Jefferies but said it has no current plan to tap it, citing unchanged cash guidance through H2 2028.

Eupraxia Pharmaceuticals Inc., on November 10, 2026, announced it had signed a sales agreement with Jefferies LLC as its U.S. agent and Jefferies Securities, Inc. as its Canadian agent, establishing an at-the-market equity program.1

Under the arrangement, Eupraxia can offer and sell up to US$125 million, or the Canadian dollar equivalent, in common shares through the program.1 Sales can be made by the company to the public at the discretion of management, through the agents, at prevailing market prices on the Toronto Stock Exchange, the Nasdaq Global Select Market, or other existing trading venues in Canada and the United States.1

Chief Financial Officer Alex Rothwell characterized the move as routine, saying the ATM program was put in place as a general corporate housekeeping item, consistent with industry norms.1 He added that the company's cash runway guidance from its latest quarterly financials remains unchanged, with current cash balances expected to cover planned expenses into the second half of 2028.1 He said the company does not intend to draw on the facility soon.

The program is being carried out in Canada under a prospectus supplement dated November 10, 2026 to the company's final short form base shelf prospectus dated August 18, 20261, and in the United States under a parallel supplement tied to a U.S. base shelf prospectus forming part of a Form F-10 registration statement, file number 333-298036, which became effective August 24, 2026.1

The offering will end when all shares under the agreement are sold, when either the agents or the company terminate the agreement as permitted, or when the Canadian shelf prospectus expires.1 Eupraxia describes itself as a clinical-stage biotechnology company focused on developing locally delivered, extended-release products aimed at therapeutic areas with high unmet medical need.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.